Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixazomib - Takeda Oncology

Next Previous
X
Search
Drug Profile

Ixazomib - Takeda Oncology

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals; University of California, San Diego
  • Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Antivirals; Chlorobenzenes; Organic boron compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II HIV infections
  • No development reported Lupus nephritis; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Bladder cancer; Solid tumours

Most Recent Events

  • 03 Jul 2024 Takeda completes a phase II clinical trials in Amyloidosis in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)
  • 03 Jul 2024 Takeda completes a phase II trial for Multiple myeloma in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)
  • 03 Jul 2024 Takeda completes a phase-II clinical trials in Lymphoma in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top